Imunon appoints Dr. Douglas Faller as CMO; Phase 3 trial on track for Q1 2025

Imunon, Inc.

Dr. Douglas Faller appointed Chief Medical Officer effective Feb 18, 2025, to lead clinical strategy.
Lead program IMNN-001 for advanced ovarian cancer on track to enter Phase 3 pivotal trial in Q1 2025.
Compensation: $480k salary, 40% bonus target, inducement options for 100,000 shares with 4-year vesting.
Dr. Faller brings 30+ years of oncology/immunology experience from Takeda, Skyhawk, and academic roles.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Douglas Faller

Chief Medical Officer

IMNN · Imunon, Inc.

Effective: 2025-02-18
Filed: February 10, 2025, 6:59 PM ET

On February 9, 2025, the Board of Directors of Imunon, Inc. (the “Company”) appointed Dr. Douglas Faller (age 72) as Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Douglas Faller was appointed as Chief Medical Officer at Imunon, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On February 9, 2025, the Board of Directors of Imunon, Inc. (the “Company”) appointed Dr. Douglas Faller (age 72) as Chief Medical Officer.

View on SEC.gov

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-005536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.